Bodmer Alexandre, Goetsch Liliane, Favet Laurence, Bailly Christian, Corvaia Nathalie, Dietrich Pierre-Yves
Hôpitaux universitaires de Genève, Centre d'oncologie, rue Gabrielle Perret Gentil, 1211 Genève 14, France.
Med Sci (Paris). 2009 Dec;25(12):1090-8. doi: 10.1051/medsci/200925121090.
Recent biotechnological advances allowed the development of a novel class of anti-cancer drugs called monoclonal antibodies (mAb). To illustrate the potential of these new agents, two mAbs used in daily practice (i.e., trastuzumab and cetuximab) and two promising targets (i.e., IGF-1R and c-Met) for which mAbs should be available in a near future are discussed here. Trastuzumab and cetuximab deeply changed treatment strategies for breast, colon, and head and neck cancers. However their efficacy is observed in a fraction of patients only and is often time limited. Thus, current challenges are to better understand the mechanisms of action of mAbs, to identify mechanisms of resistance, to exploit the synergy between mAbs and chemotherapy drugs, and to better select patients with a potential benefit. Resolving these issues should pave the way for tailored treatment according to tumor and patient characteristics.
近期生物技术的进展促使了一类名为单克隆抗体（mAb）的新型抗癌药物的研发。为了说明这些新型药物的潜力，本文讨论了两种日常实践中使用的单克隆抗体（即曲妥珠单抗和西妥昔单抗）以及在不久的将来有望获得单克隆抗体治疗的两个靶点（即胰岛素样生长因子-1受体（IGF-1R）和c-Met）。曲妥珠单抗和西妥昔单抗深刻改变了乳腺癌、结肠癌以及头颈癌的治疗策略。然而，它们的疗效仅在部分患者中观察到，且往往时间有限。因此，当前面临的挑战是更好地理解单克隆抗体的作用机制，识别耐药机制，利用单克隆抗体与化疗药物之间的协同作用，以及更好地选择可能受益的患者。解决这些问题将为根据肿瘤和患者特征进行个性化治疗铺平道路。
